EXEL – Looking for Direction Ahead of the PDUFA date

Exelixis (NASDAQ: EXEL) On 5/30/12, Exelixis submitted their NDA for Cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). They were subsequently granted priority review with a PDUFA date set for 11/29/12. Recently, the FDA announced they had planned to hold an Advisory Committee to discuss this […]

BMRN – A Busy Quarter Ahead.

BioMarin (NASDAQ:BMRN) $BMRN is a ticker that every biotech investor or trader would like to see it in his portfolio. Just look at the weekly chart to understand the huge & steady uptrend, $BMRN had a huge run since Mar 2009 starting at $10 and running to $41 these days, it’s more than 400% in […]

ZIOP – Trading In an Uptrend Channel

Ziopharm(NASDAQ: ZIOP) In Patrick’s latest article “Smallcap Phase 3 data expected by year-end 2012” he mentions Ziopharm’s current Phase 3 trial of Palifosfamide. This Phase 3 trial, known as PICASSO 3, is testing Palifosfamide (Zymafos or ZIO-201) in addition to Doxorubicin versus Doxorubicin in front-line metastatic soft tissue sarcoma. The trial completed enrollment on June 2nd. […]

EXEL – In A Consolidation Mode

EXEL “Exelixis” had an impressive uptrend starting in June 2012, anticipating the FDA reply for the NDA filling & priority review, starting from the $4.40 area, reaching the $6.95 point on the day of the announcement that the FDA accepted its potential medullary thyroid cancer (MTC) treatment, cabozantinib, for priority review , which is shorter […]